Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

Proteasome Inhibitors Induce p53-Independent Apoptosis in Human Cancer Cells

(2011) Bulbul Pandit et al.   AMERICAN JOURNAL OF PATHOLOGY

Increased Copy Number of the Interleukin-6 Receptor Gene Is Associated with Adverse Survival in Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation

(2011) Seon Young Kim et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2

(2011) N. C. Munshi et al.   BLOOD

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

(2011) G. J. Morgan et al.   BLOOD

Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective

(2011) H. Ludwig et al.   ONCOLOGIST

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

(2010) P. G. Richardson et al.   BLOOD

Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone

(2010) Ulrike Klein et al.   CANCER

Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation

(2010) K. Neben et al.   HAEMATOLOGICA

Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)

(2010) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13

(2009) D. Reece et al.   BLOOD

Response: G6PD deficiency and cerebrovascular disease in sickle cell anemia?

(2009) F. Bernaudin et al.   BLOOD

Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells

(2009) T. Hideshima et al.   BLOOD

TP53deletion is not an adverse feature in multiple myeloma treated with total therapy 3

(2009) John D. Shaughnessy et al.   BRITISH JOURNAL OF HAEMATOLOGY

Multiple myeloma

(2009) Marc S Raab et al.   LANCET

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

(2009) R Fonseca et al.   LEUKEMIA

An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma

(2008) W. Xiong et al.   BLOOD

Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling

(2008) M. S. Raab et al.   BLOOD

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE